Aortic Diseases Clinical Trial
Official title:
Effect of DDD Pacing Titrated by Stepwise Changing of AVD on Aortic dP/dt
Verified date | September 2018 |
Source | Istanbul University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The maximum value of rate of left ventricular pressure increase, denoted by left ventricular
peak dP/dt value (dP/dt max), corresponds to the highest point on the curve of first
derivative of ventricular pressure curve with respect to time. It is one of the important
systolic performance parameters, which is primarily determined by ventricular contractility,
and emerges in isovolumetric contraction phase when aortic valves are closed. Thus it is not
influenced by parameters beyond ventricle such as aortic valve area, aortic elastance and
peripheral resistance. Despite these unique advantageous, the main reason for its limited
usage in assessing ventricular systolic performance instead of commonly used ejection
fraction is the difficulties in its calculation, which requires incessant intraventricular
pressure recordings.
The maximum value of acceleration rate of aortic pressure increase can be named as aortic
peak dP/dt. It, likewise, corresponds to the maximum value of first derivative of pressure
curve with respect to time.
Since it is one of the principal determining factors of aortic peak dP/dt, changing left
ventricular contractility thereby left ventricular peak dP/dt value is expected to change
aortic peak dP/dt in the same direction since all other variables being unchanged. Yet to
conclude the extent of this association and magnitude of change, measuring these parameters
for various contractility levels is necessary. In addition, impact of decreasing left
ventricular peak dP/dt by gradually lowering ventricular contractility upon aortic peak dP/dt
has not been investigated in previous studies.
In the present study, changes in left ventricular and aortic peak dP/dt values in response to
gradual reduction in LV contractility with stepwise changing (decremental shortening)
atrio-ventricular delay (AVD) by dual chamber pacing will be investigated in patients without
systolic dysfunction.
Status | Completed |
Enrollment | 34 |
Est. completion date | October 15, 2018 |
Est. primary completion date | October 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: • Normal left ventricular systolic function Exclusion Criteria: - Abnormal left ventricular systolic function with ejection fraction < 50% - Presence of severe coronary artery disease - Presence of valvular heart disease |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul University, Istanbul Faculty of Medicine, Department of Cardiology | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Istanbul University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changing in aortic dP/dt in response to DDD pacing | Changing in aortic dP/dt in response to DDD pacing will be determined | At the end of the stepwise pacing procedure completed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Completed |
NCT02876263 -
Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta
|
N/A | |
Recruiting |
NCT03948555 -
Magnetic Resonance Imaging (MRI) for Aortic Dissection to Visualise Inflammation
|
||
Completed |
NCT02266342 -
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
|
||
Recruiting |
NCT05972018 -
Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters
|
Phase 4 | |
Completed |
NCT03727542 -
Influence of Short AV Delay Permanent Pacing on Matrix Metalloproteinase Levels
|
N/A | |
Not yet recruiting |
NCT06199401 -
Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery
|
N/A | |
Recruiting |
NCT06358248 -
Standardized Physician-modified Fenestrated Endograft Registry
|
||
Recruiting |
NCT05777681 -
Management of Aorto-iliac Infection With BioIntegral Surgical No-React® Bovine Pericardial Xenografts
|
||
Recruiting |
NCT04995640 -
CILCA Arch Registry: Management and Outcomes of Open and Endovascular Repair
|
||
Recruiting |
NCT05777460 -
Mid- and Long-term Outcomes of Custom-made Aortic Devices
|
||
Not yet recruiting |
NCT05554055 -
Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)
|
||
Unknown status |
NCT00851149 -
Pro-inflammatory Cytokines in Blood From Orthopedic Surgery Compared to Abdominal Aneurysm Repair
|
N/A | |
Recruiting |
NCT03824626 -
Biomechanical Reappraisal of Planning for Thoracic Endovascular Aortic Repair
|
||
Completed |
NCT02867501 -
Venous Distension in Patients With Aneurysmatic Arterial Disease
|
N/A | |
Completed |
NCT03617601 -
Metabolic Equivalent of Task (MET) in the Preoperative Assessment in Aortic Surgery
|
||
Completed |
NCT01775046 -
Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
|
||
Completed |
NCT01526811 -
Endurantâ„¢ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
|
||
Completed |
NCT00538421 -
Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery
|
Phase 4 |